Health Care Cost

The findings emphasize a need for policies that may offset the impact of direct and indirect costs for patients with breast cancer.

The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.

Drug costs, particularly for immunotherapies, contributed to the rising cost of care during the last 6 months of life for a fee-for-service Medicare beneficiary, according to a recent study.

Virtual care not only means saved time and costs for employees, but improvements to employers' bottom lines, through more proactive management of health concerns, notes UCM Digital Health CEO and co-founder Keith Algozzine.

In this column, a health insurance executive discusses 2 ways to address rising inflation, including moving past the traditional fee-for-service payment model.

The bill could have saved CMS about $26.5 billion had it been in place from 2018-2020, the study showed.

CDC warns against EzriCare Artificial Tears, which were recalled by the manufacturer; certain weight loss drugs not covered by most payers; Mississippi's Republican governor denies being privately in support of Medicaid expansion.

The first of at least 8 adalimumab biosimilars has finally launched in the United States after being kept off the market for years due to settlement agreements with the maker of the reference product, Humira.

The United States possesses the highest infant and maternal mortality rates compared with any other high-income country, even though it spends the most on health care.

An HHS report said that if the Inflation Reduction Act (IRA) had been implemented in 2020, Medicare Part D beneficiaries could have saved a total of $734 million, averaging out to about $500 per member.

A new study estimated Medicare drug price negotiation savings; food benefits provided under the Supplemental Nutrition Assistance Program (SNAP) will return to prepandemic amounts; pharmacies reduce hours to cope with staffing shortages, improve work-life balance.

Multiple adalimumab biosimilars will hit the US market in 2023, but the drug is still projected to have the largest price increase for the calendar year starting July 1.

A real-world study of health care resource utilization (HCRU) in patients with myasthenia gravis on second-line therapy identified the factors that led to increased financial burdens.

Adults with diabetes who were forced to switch from an employer-sponsored health plan to a high-deductible health plan (HDHP) were 25% more likely to require an emergency department (ED) or hospital visit for hyperglycemia, but not for hypoglycemia, than those who did not switch plans.

Certain variables have been shown to have both positive and negative influences on the willingness to pay for sleep disturbance treatment, such as wealth, insurance coverage, quality of life, and age.

Amazon’s announcement of a prescription subscription service that charges a flat monthly fee instead of offering discounts on each prescription fill represents the retail giant’s latest foray into the health care space.

Eli Lilly will tack on $450 million more to increase capacity in a diabetes drug plant in light of shortages; patients emailing and messaging medical providers online might be charged; 57% of adults in a recent survey think that the federal government should secure health care coverage for all Americans.

As the country hits the debt limit spending on Medicare and Medicaid may be at risk; the Agriculture Department targets fraudulent claims in products labeled as organic; first cases of drug-resistant gonorrhea strain found.

Patients with chronic obstructive pulmonary disease (COPD) are more likely to die in the year after undergoing surgery and rack up higher health care costs post-operation, study finds.

No difference in treatment efficacy was observed between intranasal mometasone furoate and saline for the management of sleep-disordered breathing (SDB) symptoms in children, with findings indicating that almost one-half of children with SDB could be initially managed in the primary care setting.

Two ranibizumab biosimilars launched in the United States in 2022, but a new report shows comfort and familiarity with biosimilars has gone down compared with a year ago.

Greater availability of naloxone spray, including over the counter, may reduce opioid overdoses; vaccination rates drop once again for US children; some experts question the necessity of the updated COVID-19 booster shot.

Expanded health coverage sees an increase in enrollments; Antiabortion activists protest against CVS and Walgreens; $26,500 Alzheimer’s drug limits affordability

The 10 drugs selected for Medicare Part D price negotiation with HHS will be announced on September 1, 2023, HHS said Wednesday.

President Joe Biden expected to renew COVID-19 public health emergency (PHE) one more time; Bristol Myers Squibb and Pfizer are denied by the Supreme Court; funding for the 988 mental health helpline expands inclusivity efforts.

The FDA’s approval of lecanemab for Alzheimer disease is very important, but there will remain significant challenges around pricing and access that will need to be addressed to deliver on the promise the therapy actually represents, said Alvaro Pascual-Leone, MD, PhD, of Harvard Medical School.

We want to make it easy for our patients to manage and navigate the financial toxicity they encounter from their cancer care, noted Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health and the Allina Health Cancer Institute.

Dual-regimen abortion pills authorized for pharmacy sale by FDA; health professionals turn a critical eye to US concerns about COVID-19 in China while domestic cases rise here as vaccination rates drop; drug manufacturers are collectively raising prices early this month on medications from autoimmune treatments to shingles vaccines to cancer treatments.

The Chinese government warns of backlash for countries requiring COVID-19 testing of travelers from China; monoclonal antibody drugs show some promise against infectious diseases, but costs need to be lower; the role of FDA and Biogen in approving Alzheimer drug Aduhelm is detailed in a scathing Congressional committee report.